Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women

Hopital Lariboisière

Status: Completed

Conditions: Vertical Disease Transmission; HBV

Study type: Observational

Funder types: Other

Identifiers

NCT02044068

Liver003

Details and patient eligibility

About

Vertical HIV transmission has been dramatically reduced by the use of combined antiretroviral therapy in HIV-infected pregnant women. Among the most often used drugs, several have dual activity, against HIV and HBV: lamivudine, emtricitabine, tenofovir. Studies about vertical HBV transmission from HIV-HBV co-infected pregnant women are rare in developed countries. The study hypothesis is a major reduction of the risk of HBV vertical transmission.

Full description

Mother-to-Child HIV transmission has been dramatically reduced by the use of combined antiretroviral therapy in HIV-infected pregnant women, both in developed and in developing countries. Among the most often used drugs, several have dual activity, against HIV and HBV: lamivudine, emtricitabine, tenofovir; they can be used as a combo, as tenofovir+emtricitabine for instance. Studies about vertical HBV transmission from HIV-HBV co-infected pregnant women are rare in developed countries. The study hypothesis is a major reduction of the risk of HBV vertical transmission in this context, justifying this retrospective study.

Enrollment: 35 patients

Sex: All

Ages: 9 months to 15 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• children born in the Maternity Department from HIV-HBV co-infected women
• whose mother was given a treatment with dual activity (HIV and HBV) during pregnancy

Exclusion criteria

• no

Trial design

35 participants in 1 patient group

children born from HIV-HBV women

Description:

Studying retrospectively their status for HBs Ag and HBc Ab